Title (en)

3-PYRROLYL UREA DERIVATIVES AND THEIR USE AS ANTIVIRAL AGENTS

Title (de)

3-PYRROLYL-HARNSTOFF- DERIVATE UND IHRE VERWENDUNG ALS ANTIVIRALE MITTEL

Title (fr)

DERIVES D'UREE 3-PYRROLYLE ET LEUR UTILISATION EN TANT QU'AGENTS ANTIVIRAUX

Publication

EP 1572642 A1 20050914 (DE)

Application

EP 03789084 A 20031126

Priority

- DE 10257358 A 20021209
- EP 0313278 W 20031126

Abstract (en)

[origin: WO2004052852A1] The invention relates to substituted pyrroles of formula (I), in which: R<1> represents -OR<8> or -NR<9>R<10>; R<2> represents hydrogen, C1-C6 alkyl or aryl, whereby R<2> as an alkyl can be substituted with 0, 1, 2 or 3 substituents R<2-1 >independently of one another, selected from the group comprising halogen, hydroxy, C1-C6 alkoxy, hydroxycarbonyl, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyloxy, amino, C1-C6 alkylamino, aminocarbonyl, C1-C6 alkylaminocarbonyl, C3-C8 cycloalkyl, a 5- to 10-membered heterocyclyl, C6-C10 aryl, phenoxy and a 5- to 10-membered heteroaryl and whereby R<2> as an aryl can be substituted with 0, 1, 2 or 3 substituents R<2-2> independently of one another, selected from the group comprising halogen, hydroxy, nitro, cyano, trifluoromethyl, trifluoromethoxy, C1-C6 alkyl, C1-C6 alkoxy, hydroxycarbonyl, C1-C6 alkoxycarbonyl, amino, C1-C6 alkylamino, aminocarbonyl, C1-C6 alkylaminocarbonyl, C3-C8 cycloalkyl, a 5- to 10-membered heterocyclyl, C6-C10 aryl and a 5- to 10-membered heteroaryl; R<3> and R<4> independently of one another represent hydrogen or C1-C6 alkyl; R<5> and R<6> independently of one another represent hydrogen or C1-C6 alkyl; and R<7> represents a 3- to 12-membered carbocyclyl, whereby the carbocyclyl can be substituted with 0, 1, 2, 3, 4 or 5 substituents independently of one another, selected from the group comprising halogen, hydroxy, C1-C6 alkyl and C1-C6 alkoxy. The invention also relates to a method for producing said pyrroles, to their use for the treatment and/or prophylaxis of diseases, in addition to their use for producing medicaments for the treatment and/or prophylaxis of diseases, notably to their use as antiviral agents, in particular against cytomegaloviruses.

IPC 1-7

C07D 207/34; A61K 31/40; A61K 31/402; A61K 31/4025; C07D 401/06; C07D 401/12; C07D 403/06; C07D 403/12; C07D 405/12; C07D 413/06; C07D 405/06

IPC 8 full level

C07D 207/34 (2006.01); **C07D 401/06** (2006.01); **C07D 401/12** (2006.01); **C07D 403/06** (2006.01); **C07D 403/12** (2006.01); **C07D 405/06** (2006.01); **C07D 405/12** (2006.01); **C07D 413/06** (2006.01)

CPC (source: EP)

A61P 31/12 (2017.12); **C07D 207/34** (2013.01); **C07D 401/06** (2013.01); **C07D 401/12** (2013.01); **C07D 403/06** (2013.01); **C07D 403/12** (2013.01); **C07D 405/06** (2013.01); **C07D 405/12** (2013.01); **C07D 413/06** (2013.01)

Citation (search report)

See references of WO 2004052852A1

Designated contracting state (EPC)

DE ES FR GB IT

DOCDB simple family (publication)

WO 2004052852 A1 20040624; AU 2003293723 A1 20040630; CA 2508788 A1 20040624; DE 10257358 A1 20040708; EP 1572642 A1 20050914

DOCDB simple family (application)

EP 0313278 W 20031126; AU 2003293723 A 20031126; CA 2508788 A 20031126; DE 10257358 A 20021209; EP 03789084 A 20031126